B. Frimodt-Moller

发表

Ramucirumab or placebo plus erlotinib in EGFR‐mutated, metastatic non‐small‐cell lung cancer: East Asian subset of RELAY

J. Shih, Keunchil Park, C. Chiu, 2020, Cancer science.

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.

J. Shih, Keunchil Park, S. Novello, 2019, The Lancet. Oncology.

RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability

J. Shih, S. Novello, M. Reck, 2021, Drug Safety.

A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer.

J. Vansteenkiste, F. Barlesi, B. Besse, 2019, Lung Cancer.

Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer.

A. Schneeweiss, R. Kreienberg, J. Mayordomo, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset

Y. Ohe, K. Kiura, K. Goto, 2021, JTO clinical and research reports.

RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).

J. Shih, Keunchil Park, S. Novello, 2019, Journal of Clinical Oncology.

PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.

C. Obasaju, M. Socinski, R. Govindan, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dual EGFR/VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC.

X. Le, J. Goldman, M. Reck, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small-cell lung cancer

K. Yoh, D. Moro-Sibilot, A. Zimmermann, 2020, Current medical research and opinion.

RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer

J. Shih, Keunchil Park, L. Paz-Ares, 2021, Clinical Cancer Research.

Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer

D. Shin, C. Reuter, R. Hitt, 2012, Cancer.

A Phase II Multicenter Study of Two Different Dosages of Pemetrexed Given in Combination With Cyclophosphamide as First-Line Treatment in Patients With Locally Advanced or Metastatic Breast Cancer

K. Krejcy, A. Manikhas, I. Láng, 2012 .

RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis.

S. Novello, D. Moro-Sibilot, A. Zimmermann, 2021, Cancer treatment and research communications.

Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer.

Tuan S. Nguyen, K. Syrigos, F. Mayer, 2013, Lung cancer.

RELAY, erlotinib plus ramucirumab or placebo in untreated EGFR-mutated metastatic NSCLC: outcomes by EGFR mutation type

T. Seto, M. Reck, E. Nadal, 2020, Pneumologie.